Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting

Journal of Bone Oncology

Volumn 4, Issue 2, 2015, Pages 54-58

  Jacobs, Carmel ^a   Amir, Eitan ^b   Paterson, Alexander ^c   Zhu, Xiaofu ^a   Clemons, Mark ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Bone health; Bone metastases; Bone targeted agents; Cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE METASTASIS; BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; DRUG INDICATION; EARLY CANCER; FEMALE; HIGH RISK POPULATION; HUMAN; MEDICAL SOCIETY; META ANALYSIS (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 84933050150     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2015.06.001     Document Type: Review

References (46)

1. M. Fralick, N. Bouganim, R. Kremer, N. Kekre, S. Robertson, and L. Vandermeer Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients-preliminary results J Bone Oncol 1 3 2012 69 73
2. K. Russell, E. Amir, A. Paterson, R. Josse, C. Addison, and I. Kuchuk Does estrogen play a role in response to adjuvant bone-targeted therapies? J Bone Oncol 2 4 2013 167 173
3. C.L. Addison, G.R. Pond, H. Zhao, S. Mazzarello, L. Vandermeer, and R. Goldstein Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases SpringerPlus 3 2014 577
4. C.L. Addison, N. Bouganim, J. Hilton, L. Vandemeer, S. Dent, E. Amir, et al., A Phase II, multicenter trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events, Breast Cancer Res Treat. 2014;144(3):615-24. 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.
5. B. Hutton, C. Addison, K. Campbell, D. Fergusson, S. Mazarello, and M. Clemons A systematic review of dosing frequency with bone targeted agents for patients with bone metastases from breast cancer J Bone Oncol 2 2013 123 131
6. I. Kuchuk, B. Hutton, P. Moretto, T. Ng, C.L. Addison, and M. Clemons Incidence, consequences and treatment of bone metastases in breast cancer patients - experience from a single cancer centre J Bone Oncol 2 4 2013 137 144
7. B. Hutton, P. Morretto, U. Emmenegger, S. Mazzarello, I. Kuchuk, and C.L. Addison Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: a patient survey J Bone Oncol 2 3 2013 105 109
8. B. Hutton, C. Addison, S. Mazzarello, A.A. Joy, N. Bouganim, and D. Fergusson De-escalated administration of bone-targeted agents in patients with breast and prostate cancer - a survey of Canadian oncologists J Bone Oncol 2 2 2013 77 83
9. M.J. Clemons, B. Cochrane, G.R. Pond, N. Califaretti, S.K. Chia, and R.A. Dent Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study Breast Cancer Res Treat 146 1 2014 153 162
10. I. Kuchuk, D. Simos, C.L. Addison, and M. Clemons A national portfolio of bone oncology trials - the Canadian experience in 2012 J Bone Oncol 1 3 2012 95 100
11. I. Kuchuk, S. Mazzarello, K. Butterfield, A. Appleton, C.L. Addison, and M. Clemons Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists J Bone Oncol 2 1 2013 38 46
12. S. Mazzarello, M. Clemons, I.D. Graham, C. Jacobs, Surviving surveys, J Oncol Pract (2014). (August 5), 001484
13. Coleman R, Gnant M, Paterson A, et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomized trials. 2013 San Antonio Breast Cancer Symposium; 12 December 2013.
14. C.H. Van Poznak, S. Temin, G.C. Yee, N.A. Janjan, W.E. Barlow, and J.S. Biermann American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer J Clin Oncoly: Off J Am Soc Clin Oncol 29 9 2011 1221 1227
15. F. Cardoso, N. Harbeck, L. Fallowfield, S. Kyriakides, and E. Senkus Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol: Off J Eur Soc Med Oncol 23 Suppl 7 2012 vii11 vii19
16. M. Clemons, K. Russell, L. Costa, and C.L. Addison Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated? Breast Cancer Res Treat 134 2 2012 453 457
17. R. Aft, M. Naughton, K. Trinkaus, M. Watson, L. Ylagan, and M. Chavez-MacGregor Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial Lancet Oncol 11 5 2010 421 428
18. E. Amir, A. Ocana, B. Seruga, R. Josse, and M. Clemons Medical oncology: zoledronic acid for breast cancer therapy-induced bone loss Nat Rev Clin Oncol 7 4 2010 187 188
19. I. Ben-Aharon, L. Vidal, S. Rizel, R. Yerushalmi, O. Shpilberg, and A. Sulkes Bisphosphonates in the adjuvant setting of breast cancer therapy - effect on survival: a systematic review and meta-analysis PloS ONE 8 8 2013 e70044
20. M.C. Winter, I. Holen, and R.E. Coleman Exploring the anti-tumour activity of bisphosphonates in early breast cancer Cancer Treat Rev 34 5 2008 453 475
21. M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, D. Heck, and C. Menzel Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Lancet Oncol 12 7 2011 631 641
22. A.H. Paterson, S.J. Anderson, B.C. Lembersky, L. Fehrenbacher, C.I. Falkson, and K.M. King Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial Lancet Oncol 13 7 2012 734 742
23. R. Coleman, D. Cameron, D. Dodwell, R. Bell, C. Wilson, and E. Rathbone Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial Lancet Oncol 15 9 2014 997 1006
24. G. von Minckwitz, V. Möbus, A. Schneeweiss, J. Huober, C. Thomssen, M. Untch, et al., German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer, Clin Oncol 2013; 31(28):3531-9
25. T. Powles, S. Paterson, J.A. Kanis, E. McCloskey, S. Ashley, and A. Tidy Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer J Clin Oncol 20 15 2002 3219 3224
26. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 8 2002 584 593
27. K. Russell, M. Clemons, L. Costa, and C.L. Addison Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there? J Bone Oncol 1 1 2012 12 17
28. P. Clezardin Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities BoneKEy Rep 2 2013 267
29. R. Suriano, D. Chaudhuri, R.S. Johnson, E. Lambers, B.T. Ashok, and R. Kishore 17Beta-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors Cancer Res 68 15 2008 6038 6042
30. S. Omoigui The Interleukin-6 inflammation pathway from cholesterol to aging - role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases Immun Ageing 4 1 2007
31. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 2005 1687 1717
32. Early Breast Cancer Trialists' Collaborative Group Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 9814 2012 432 444
33. R. Eastell, J.E. Adams, R.E. Coleman, A. Howell, R.A. Hannon, and J. Cuzick Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230 J Clin Oncol: Off J Am Soc Clinl Oncol 26 7 2008 1051 1057
34. R.E. Coleman, L.M. Banks, S.I. Girgis, L.S. Kilburn, E. Vrdoljak, and J. Fox Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 2 2007 119 127
35. E.A. Perez, R.G. Josse, K.I. Pritchard, J.N. Ingle, S. Martino, and B.P. Findlay Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 J Clin Oncol: Off J Am Soc Clin Oncol 24 22 2006 3629 3635
36. S0307 Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer 2014 [cited 2014 29 December]. Available from: (https://clinicaltrials.gov/ct2/show/NCT00127205).
37. Gralow J, Barlow W, Paterson AHG, Lew D, Stopeck A, Hayes DF, et al., editor. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. ASCO Annual Meeting. Chicago; 2014.
38. A.M. Brufsky, W.G. Harker, J.T. Beck, L. Bosserman, C. Vogel, and C. Seidler Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole Cancer 118 5 2012 1192 1201
39. R. Coleman, R. de Boer, H. Eidtmann, A. Llombart, N. Davidson, and P. Neven Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results Ann Oncol: Off J Eur Soc Med Oncol 24 2 2013 398 405
40. A. Llombart, A. Frassoldati, O. Paija, H.P. Sleeboom, G. Jerusalem, and J. Mebis Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial Clin Breast Cancer 12 1 2012 40 48
41. R.E. Coleman, H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, and M. Keane Breast-Cancer Adjuvant Therapy with Zoledronic Acid N Engl J Med 365 15 2011 1396 1405
42. von Minckwitz G, Rezai M, Eidtmann H, Tesch H, et al., (eds). Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer - The phase III NATANstudy (GBG 36/ABCSG XX). San Antonio Breast Cancer Symposium. San Antonio; 2013.
43. G. von Minckwitz, V. Mobus, A. Schneeweiss, J. Huober, C. Thomssen, and M. Untch German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer J Clin Oncol: Off J Am Soc Clin Oncol 31 28 2013 3531 3539
44. Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (d-CARE) [cited 29.12.14]. Available from: (https://clinicaltrials.gov/ct2/show/NCT01077154).
45. P.A. Francis, M.M. Regan, G.F. Fleming, I. Lang, E. Ciruelos, M. Bellet, et al., Adjuvant ovarian suppression in premenopausal breast cancer, N Engl J Med 2015; 372:436-446
46. O. Pagani, M.M. Regan, B.A. Walley, G.F. Fleming, M. Colleoni, and I. Lang Adjuvant exemestane with ovarian suppression in premenopausal breast cancer N Engl J Med 371 2 2014 107 118